Parabilis (PBLS) director Edward Fitzgerald details preferred stock and option holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Parabilis Medicines, Inc. director Edward M. Fitzgerald filed an initial ownership report showing his existing preferred stock and option positions in the company. The filing lists Series B, C and F Preferred Stock that are each convertible into Common Stock on fixed ratios and will automatically convert into specified numbers of Common shares immediately prior to the closing of the company’s initial public offering, without additional payment. Fitzgerald also holds stock options over Common Stock, including 32,490 shares at an exercise price of $3.14 per share expiring in 2036, 16,245 shares at $4.82 per share expiring in 2031, and 16,245 shares at $1.85 per share expiring in 2027. One option grant is fully vested, while another is scheduled to vest in 48 equal monthly installments starting February 24, 2026, subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
FITZGERALD EDWARD M
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Series B Preferred Stock | -- | -- | -- |
| holding | Series C Preferred Stock | -- | -- | -- |
| holding | Series F Preferred Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 16,245 shares (Direct, null);
Series B Preferred Stock — 5,539 shares (Direct, null);
Series C Preferred Stock — 3,878 shares (Direct, null);
Series F Preferred Stock — 5,271 shares (Direct, null)
Footnotes (1)
- The shares subject to this option are fully vested. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 24, 2026, subject to the Reporting Person's continued service on each such vesting date. Each share of Series B Preferred Stock is convertible into Common Stock on a 1 to 1.0389 basis at any time at the option of the holder, and will automatically convert into the number of shares shown in Column 3 immediately prior to the closing of the Issuer's initial public offering (the "IPO") and without payment of consideration. The Series B Preferred Stock has no expiration date. Each share of Series C Preferred Stock is convertible into Common Stock on a 1 to 1.0578 basis at any time at the option of the holder, and will automatically convert into the number of shares shown in Column 3 immediately prior to the closing of the IPO and without payment of consideration. The Series C Preferred Stock has no expiration date. Each share of Series F Preferred Stock is convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and will automatically convert into the number of shares shown in Column 3 immediately prior to the closing of the IPO and without payment of consideration. The Series F Preferred Stock has no expiration date.
Key Figures
Series B underlying shares: 5,539 shares
Series C underlying shares: 3,878 shares
Series F underlying shares: 5,271 shares
+4 more
7 metrics
Series B underlying shares
5,539 shares
Underlying Common Stock from Series B Preferred
Series C underlying shares
3,878 shares
Underlying Common Stock from Series C Preferred
Series F underlying shares
5,271 shares
Underlying Common Stock from Series F Preferred
Option at $3.14
32,490 shares at $3.14/share
Stock option expiring February 23, 2036
Option at $4.82
16,245 shares at $4.82/share
Stock option expiring May 12, 2031
Option at $1.85
16,245 shares at $1.85/share
Stock option expiring July 30, 2027
Vesting schedule
48 monthly installments
Option vesting from February 24, 2026, with continued service
Key Terms
Series B Preferred Stock, Series C Preferred Stock, Series F Preferred Stock, Stock Option (right to buy), +1 more
5 terms
Series B Preferred Stock financial
"Each share of Series B Preferred Stock is convertible into Common Stock on a 1 to 1.0389 basis"
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
Series C Preferred Stock financial
"Each share of Series C Preferred Stock is convertible into Common Stock on a 1 to 1.0578 basis"
A Series C preferred stock is a specific class of ownership issued during a later funding round that gives holders priority over common shareholders for getting paid and receiving dividends, like having a reserved lane in traffic when money is distributed. It often includes agreed rights such as a fixed payout, protection against dilution, and the option to convert into common shares, so investors treat it as a mix of safety and upside potential.
Series F Preferred Stock financial
"Each share of Series F Preferred Stock is convertible into Common Stock on a 1 to 0.6498 basis"
Series F preferred stock is a class of company shares that gives holders priority over common shareholders for dividend payments and for getting money back if the company is sold or liquidated, much like a ticket that moves you to the front of the line. These shares often carry a fixed dividend and special rights—sometimes including conversion into common stock—so investors consider them when weighing income, downside protection and potential ownership dilution.
Stock Option (right to buy) financial
"Stock Option (right to buy) with underlying Common Stock shares and exercise prices"
initial public offering (the "IPO") financial
"will automatically convert into the number of shares shown in Column 3 immediately prior to the closing of the Issuer's initial public offering (the "IPO")"
FAQ
What does the Parabilis Medicines (PBLS) Form 3 filing show for Edward M. Fitzgerald?
The Form 3 shows director Edward M. Fitzgerald’s existing holdings in Parabilis Medicines, including convertible Series B, C and F Preferred Stock into Common Stock and several stock option grants over Common shares, with detailed exercise prices, share amounts and expirations.
What stock options in Parabilis Medicines (PBLS) does Edward Fitzgerald hold?
Edward Fitzgerald holds options over 32,490 Common shares at $3.14 per share expiring February 23, 2036, 16,245 shares at $4.82 per share expiring May 12, 2031, and 16,245 shares at $1.85 per share expiring July 30, 2027, all reported as directly owned.
What are the vesting terms of Edward Fitzgerald’s Parabilis Medicines (PBLS) stock options?
One option grant is fully vested, meaning all related shares are currently exercisable. Another grant vests in 48 equal monthly installments beginning February 24, 2026, contingent on Fitzgerald’s continued service with Parabilis Medicines on each scheduled vesting date.